Replication-competent or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus (RSV) Antigens Protect Mice Against RSV Challenge

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2001 Oct 17

PMID 11602747

Citations 59

Authors

J S Kahn

A Roberts

C Weibel

L Buonocore

J K Rose

Affiliations

Soon will be listed here.

Abstract

Foreign glycoproteins expressed in recombinant vesicular stomatitis virus (VSV) can elicit specific and protective immunity in the mouse model. We have previously demonstrated the expression of respiratory syncytial virus (RSV) G (attachment) and F (fusion) glycoprotein genes in recombinant VSV. In this study, we demonstrate the expression of RSV F and G glycoproteins in attenuated, nonpropagating VSVs which lack the VSV G gene (VSVDeltaG) and the incorporation of these RSV proteins into recombinant virions. We also show that intranasal vaccination of mice with nondefective VSV recombinants expressing RSV G (VSV-RSV G) or RSV F (VSV-RSV F) elicited RSV-specific antibodies in serum (by enzyme-linked immunosorbent assay [ELISA]) as well as neutralizing antibodies to RSV and afford complete protection against RSV challenge. In contrast, VSVDeltaG-RSV F induced detectable serum antibodies to RSV by ELISA, but no detectable neutralizing antibodies, yet it still protected from RSV challenge. VSVDeltaG-RSV G failed to induce any detectable serum (by ELISA) or neutralizing antibodies and failed to protect from RSV challenge. The attenuated, nonpropagating VSVDeltaG-RSV F is a particularly attractive candidate for a live attenuated recombinant RSV vaccine.

Citing Articles

Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration.

Gobel S, Pelz L, Silva C, Bruhlmann B, Hill C, Altomonte J Appl Microbiol Biotechnol. 2024; 108(1):240.

PMID: 38413399 PMC: 10899354. DOI: 10.1007/s00253-024-13078-6.

Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?.

Zhang Y, Nagalo B Front Immunol. 2022; 13:898631.

PMID: 35837384 PMC: 9273848. DOI: 10.3389/fimmu.2022.898631.

Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.

Binjawadagi B, Ma Y, Binjawadagi R, Brakel K, Harder O, Peeples M J Virol. 2021; 95(6).

PMID: 33408176 PMC: 8094962. DOI: 10.1128/JVI.02345-20.

Rhabdoviruses as vectors for vaccines and therapeutics.

Scher G, Schnell M Curr Opin Virol. 2020; 44:169-182.

PMID: 33130500 PMC: 8331071. DOI: 10.1016/j.coviro.2020.09.003.

Engineering of Live Chimeric Vaccines against Human Metapneumovirus.

Ogonczyk Makowska D, Hamelin M, Boivin G Pathogens. 2020; 9(2).

PMID: 32093057 PMC: 7168645. DOI: 10.3390/pathogens9020135.

References

Shay D, Holman R, Newman R, Liu L, Stout J, Anderson L . Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999; 282(15):1440-6. DOI: 10.1001/jama.282.15.1440. View

Piedra P, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman D . Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J. 1996; 15(1):23-31. DOI: 10.1097/00006454-199601000-00006. View

Couch R, Englund J, Whimbey E . Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997; 102(3A):2-9; discussion 25-6. PMC: 7124320. DOI: 10.1016/s0002-9343(97)00003-x. View

Wright P, Karron R, Belshe R, Thompson J, Crowe Jr J, Boyce T . Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis. 2000; 182(5):1331-42. DOI: 10.1086/315859. View

Rose N, Roberts A, Buonocore L, Rose J . Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol. 2000; 74(23):10903-10. PMC: 113169. DOI: 10.1128/jvi.74.23.10903-10910.2000. View

Boelen A, Andeweg A, Kwakkel J, LOKHORST W, Bestebroer T, Dormans J . Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine. 2000; 19(7-8):982-91. DOI: 10.1016/s0264-410x(00)00213-9. View

Kapikian A, Mitchell R, Chanock R, Shvedoff R, Stewart C . An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969; 89(4):405-21. DOI: 10.1093/oxfordjournals.aje.a120954. View

Kim H, Canchola J, BRANDT C, Pyles G, Chanock R, Jensen K . Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969; 89(4):422-34. DOI: 10.1093/oxfordjournals.aje.a120955. View

Glezen P, Denny F . Epidemiology of acute lower respiratory disease in children. N Engl J Med. 1973; 288(10):498-505. DOI: 10.1056/NEJM197303082881005. View

10.

Lamprecht C, Krause H, MUFSON M . Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis. 1976; 134(3):211-7. DOI: 10.1093/infdis/134.3.211. View

11.

Henderson F, Collier A, CLYDE Jr W, Denny F . Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med. 1979; 300(10):530-4. DOI: 10.1056/NEJM197903083001004. View

12.

Glezen W, Paredes A, ALLISON J, Taber L, Frank A . Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981; 98(5):708-15. DOI: 10.1016/s0022-3476(81)80829-3. View

13.

MacDonald N, Hall C, Suffin S, Alexson C, Harris P, Manning J . Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982; 307(7):397-400. DOI: 10.1056/NEJM198208123070702. View

14.

Lefrancois L, Lyles D . The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes. Virology. 1982; 121(1):168-74. DOI: 10.1016/0042-6822(82)90126-x. View

15.

Lefrancois L . Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J Virol. 1984; 51(1):208-14. PMC: 254419. DOI: 10.1128/JVI.51.1.208-214.1984. View

16.

Wang E, Prober C, Manson B, Corey M, Levison H . Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. 1984; 311(26):1653-8. DOI: 10.1056/NEJM198412273112602. View

17.

Anderson L, Hierholzer J, Bingham P, Stone Y . Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol. 1985; 22(6):1050-2. PMC: 271877. DOI: 10.1128/jcm.22.6.1050-1052.1985. View

18.

Prince G, Hemming V, Horswood R, Chanock R . Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 1985; 3(3):193-206. DOI: 10.1016/0168-1702(85)90045-0. View

19.

Walsh E, Cote P, Fernie B, Schlesinger J, Brandriss M . Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. J Gen Virol. 1986; 67 ( Pt 3):505-13. DOI: 10.1099/0022-1317-67-3-505. View

20.

Hall C, Powell K, MacDonald N, Gala C, Menegus M, Suffin S . Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986; 315(2):77-81. DOI: 10.1056/NEJM198607103150201. View